OFFSPRING CONCEIVED THROUGH ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) HAVE NORMAL THYROID FUNCTION IN ADOLESCENCE

SummaryAim: Establishment of radioiodine treatment of feline hyperthyroidism in veterinary routine in accordance with German radiation protection regulations. Patients and methods: 35 cats with proven hyperthyroidism were treated with 131I in a special ward. Thyroid uptake and effective halflife were determined using gammacamera dosimetry. Patients were released when measured whole body activity was below the limit defined in the German “Strahlenschutzverordnung”. Results: 17/20 cats treated with 150 MBq radioiodine and 15/15 cats treated with 250 MBq had normal thyroid function after therapy, normal values for FT3 and FT4 were reached after two and normal TSH levels after three weeks. In 14 cats normal thyroid function was confirmed by controls 3-6 months later. Thyroidal iodine uptake was 24 ± 10%, effective halflife 2.5 ± 0.7 days. Whole body activity <1 MBq was reached 13 ± 4 days after application of 131I. Radiation exposure of cat owners was estimated as 1.97 Sv/MBq for adults. Conclusion: Radioiodine therapy of feline hyper-thyroidism is highly effective and safe. It can easily be performed in accordance with German radiation protection regulations, although this requires hospitalisation for approximately two weeks. Practical considerations on radiation exposure of cat owners do not justify this long interval. Regulations for the veterinary use of radioactive substances similar to existing regulations for medical use in humans are higly desirable.

Download Full-text

Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon

Journal of International Medical Research ◽

10.1177/03000605211025139 ◽

2021 ◽

Vol 49 (6) ◽

pp. 030006052110251

Author(s):

Wenfan Luo ◽

Shuai Wu ◽

Hongjie Chen ◽

Yin Wu ◽

Jie Peng

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Thyroid Function ◽

Thyroid Dysfunction ◽

Hepatitis B Surface Antigen ◽

Hbv Dna ◽

Interferon Treatment ◽

Normal Thyroid ◽

Normal Thyroid Function ◽

Hbsag Loss

Objective To investigate the influence of thyroid dysfunction on the antiviral efficacy of α-interferon in adult patients with chronic hepatitis B (CHB). Methods We performed a retrospective study of 342 patients with CHB who underwent interferon treatment for >12 weeks. Patients with thyroid dysfunction before or during treatment were defined as the thyroid dysfunction group (n = 141) and those with normal thyroid function were defined as the normal thyroid function group (n = 201). The prevalences of hepatitis B virus (HBV) DNA undetectability, low hepatitis B surface antigen (HBsAg) titre (<250 IU/mL), HBsAg loss, and hepatitis B envelope antigen loss were compared. Results During interferon treatment, 69 of 270 (25.6%) participants with normal thyroid function at baseline developed thyroid dysfunction, whereas 11 of 72 (15.3%) with thyroid dysfunction at baseline regained normal thyroid function. The thyroid dysfunction group had significantly higher prevalences of low HBsAg titre (29.8% vs. 18.9%) and HBV DNA undetectability (66.0% vs. 40.3%). Multivariate logistic regression analysis showed that thyroid dysfunction was associated with HBsAg loss (odds ratio 4.945, 95% confidence interval 1.325–18.462). Conclusions These results suggest that thyroid dysfunction is not an absolute contraindication, but is associated with HBsAg loss, in patients with CHB undergoing α-interferon treatment.

Download Full-text

Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation

BMC Endocrine Disorders ◽

10.1186/s12902-021-00715-8 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Tuo Deng ◽

Wenwen Zhang ◽

Yanling Zhang ◽

Mengqi Zhang ◽

Zhikun Huan ◽

...

Keyword(s):

Thyroid Function ◽

Thyroid Stimulating Hormone ◽

Mrna Levels ◽

Dependent Manner ◽

Osteoblast Proliferation ◽

Normal Thyroid ◽

Normal Thyroid Function ◽

Gene And Protein Expression ◽

Proliferation And Differentiation ◽

Stimulating Hormone

Abstract Background As the incidence of secretory osteoporosis has increased, bone loss, osteoporosis and their relationships with thyroid-stimulating hormone (TSH) have received increased attention. In this study, the role of TSH in bone metabolism and its possible underlying mechanisms were investigated. Methods We analyzed the serum levels of free triiodothyronine (FT3), free thyroxine (FT4), and TSH and the bone mineral density (BMD) levels of 114 men with normal thyroid function. In addition, osteoblasts from rat calvarial samples were treated with different doses of TSH for different lengths of time. The related gene and protein expression levels were investigated. Results A comparison of the BMD between the high-level and low-level serum TSH groups showed that the TSH serum concentration was positively correlated with BMD. TSH at concentrations of 10 mU/mL and 100 mU/mL significantly increased the mRNA levels of ALP, COI1 and Runx2 compared with those of the control (P < 0.05, P < 0.01). Bone morphogenetic protein (BMP)2 activity was enhanced with both increased TSH concentration and increased time. The protein levels of Runx2 and osterix were increased in a dose-dependent manner. Conclusions The circulating concentrations of TSH and BMD were positively correlated with normal thyroid function in males. TSH promoted osteoblast proliferation and differentiation in rat primary osteoblasts.

Download Full-text

Subtotal thyroidectomy: Treatment of mild or moderate congestive failure in valvular heart disease and normal thyroid function

American Heart Journal ◽

10.1016/0002-8703(48)90484-0 ◽

1948 ◽

Vol 35 (5) ◽

pp. 833

Author(s):

Hecht

Keyword(s):

Heart Disease ◽

Thyroid Function ◽

Valvular Heart Disease ◽

Subtotal Thyroidectomy ◽

Normal Thyroid ◽

Normal Thyroid Function ◽

Congestive Failure

Download Full-text

Clinical course of euthyroid subjects with positive TSH receptor antibody: how often does Graves’ disease develop?

Journal of the Endocrine Society ◽

10.1210/jendso/bvab042 ◽

2021 ◽

Author(s):

Nami Suzuki ◽

Akiko Kawaguchi ◽

Jaeduk Yoshimura Noh ◽

Ran Yoshimura ◽

Kentaro Mikura ◽

...

Keyword(s):

Thyroid Function ◽

Clinical Course ◽

Tsh Receptor ◽

Graves Disease ◽

Normal Thyroid ◽

Receptor Antibody ◽

Female Patients ◽

Tsh Receptor Antibody ◽

Normal Thyroid Function ◽

Positive Results

Abstract Background Thyroid stimulating hormone (TSH) receptor antibody (TRAb) is detected in the serum of patients with Graves’ disease (GD). This study aims to investigate the prevalence of euthyroid individuals showing positive results for TRAb and to clarify the clinical course of thyroid function and TRAb levels in these subjects. Objective Subjects were female patients who newly visited our hospital for a screening test prior to fertility treatment and showed normal thyroid function and volume without nodules between 2014 and 2017. After excluding subjects with a history of thyroid disease, 5,622 subjects were analyzed. Results Forty-seven of the 5,622 subjects showed positive results for TRAb (reference range, < 2.0 IU/L) at the initial visit. Median initial TRAb was 2.9 IU/L (range, 2.0 -14.7 IU/L) and median follow-up was 18.3 months (range, 0- 66.5 months). Six of the 47 subjects (12.8%) developed GD and median duration until development was 6.6 months (range, 1.2 -13.2 months). Median TRAb values initially and at diagnosisof GD for those 6 patients were 3.7 IU/L (range, 2.7 -5.1 IU/L) and 7.2 IU/L (range 3.6 -21.4 IU/L), respectively. TRAb results turned negative for 20 of the 47 subjects, but remained positive despite normal thyroid function in 13 of the 47 subjects. Conclusion GD developed over time in 12.8% of euthyroid young female patients showing positive TRAb within a median of 6.6 months. A positive result for TRAb itself did not mean development of GD, so other factors must be essential for the pathogenesis of GD.

Download Full-text